Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 9:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Timolol Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT02250651
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Bimatoprost SR, Sham: Applicator Without Needle, Active Comparator: Timolol 0.5%, Timolol Vehicle (placebo)
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
51
States / cities
Dothan, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Sep 2, 2026, 9:54 PM EDT
Recruiting Phase 1 Interventional

Topical 0.5% Timolol Solution for Healing Lower Extremity Wounds

NCT06941467
View directory record Official record
Conditions
Wound Healing, Mohs Micrographic Surgery
Interventions
Timolol Maleate Solution, Standard of Care
Drug · Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Sep 2, 2026, 9:54 PM EDT
Completed Phase 2 Interventional

Topical Timolol Gel for the Treatment of Infantile Hemangiomas

NCT02145884
View directory record Official record
Conditions
Hemangioma
Interventions
timolol maleate 0.5% gel
Drug
Lead sponsor
Rady Children's Hospital, San Diego
Other
Eligibility
7 Days to 6 Months
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2017 · Synced Sep 2, 2026, 9:54 PM EDT
Completed Phase 1Phase 2 Interventional

Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma

NCT00753168
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
OT-730 ophthalmic solution, timolol maleate ophthalmic solution, OT-730 placebo
Drug
Lead sponsor
Othera Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
5
States / cities
Artesia, California • Roswell, Georgia • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2009 · Synced Sep 2, 2026, 9:54 PM EDT
Completed Not applicable Interventional Results available

Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG)

NCT00824824
View directory record Official record
Conditions
Glaucoma
Interventions
Dorzolamide 2%-timolol 0.5%, Brimonidine 0.2%-0.5% timolol 0.5
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
40 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 2, 2026, 9:54 PM EDT
Completed Phase 3 Interventional Results available

Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

NCT02558374
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
AR-13324 Ophthalmic Solution 0.02%, Timolol Maleate Ophthalmic Solution 0.5% BID, Placebo
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
708 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Sep 2, 2026, 9:54 PM EDT
Completed Phase 2 Interventional Results available

Nebivolol 0.5, 1.0, or Timolol 0.5 Suspension Compared to Timolol 0.5 Solution to Treat Glaucoma/Ocular Hypertension

NCT04910100
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Nebivolol Ophthalmic Suspension 1 Percent, Nebivolol Ophthalmic Suspension 0.5 Percent, Timolol Ophthalmic Suspension 0.5 Percent, Timolol Ophthalmic Solution 0.5 Percent
Drug
Lead sponsor
Betaliq, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Sep 2, 2026, 9:54 PM EDT
Completed Phase 1 Interventional

Timolol for the Treatment of Acne and Rosacea

NCT02774590
View directory record Official record
Conditions
Acne Vulgaris, Rosacea
Interventions
Timolol
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Sep 2, 2026, 9:54 PM EDT
Completed Phase 3 Interventional Results available

Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

NCT02246764
View directory record Official record
Conditions
Ocular Hypertension, Glaucoma
Interventions
AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.02% BID, Timolol maleate Ophthalmic Solution 0.5% BID, Placebo
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
19 Years to 99 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Sep 2, 2026, 9:54 PM EDT
Completed Phase 4 Interventional Results available

Circadian Ocular Perfusion Pressure and Ocular Blood Flow

NCT00800540
View directory record Official record
Conditions
Glaucoma
Interventions
Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension, Brimonidine 20 mg/ml/Timolol 5 mg/ml eye drops solution
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Sep 2, 2026, 9:54 PM EDT
Completed Phase 4 Interventional

Bimatoprost Monotherapy vs. Dual Therapy With Travoprost and Timolol in Patients With Glaucoma and Ocular Hypertension

NCT00348023
View directory record Official record
Conditions
Glaucoma
Interventions
Bimatoprost 0.03%, Travoprost 0.004%, Timolol 0.5%
Drug
Lead sponsor
Innovative Medical
Industry
Eligibility
18 Years and older
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 8, 2007 · Synced Sep 2, 2026, 9:54 PM EDT
Completed Phase 2 Interventional Results available

A Randomized Study Evaluating the Efficacy and Safety of Timolol Ophthalmic Solution as an Acute Treatment of Migraine

NCT03836664
View directory record Official record
Conditions
Migraine
Interventions
Timolol, Placebo
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Sep 2, 2026, 9:54 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Topical Timolol: a Comparison of Surgical Outcomes

NCT05114239
View directory record Official record
Conditions
Wound Heal
Interventions
Timolol 0.25% Ophthalmic Solution, Standard Wound Care
Drug · Other
Lead sponsor
Keith G. LeBlanc, Jr, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Metairie, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 2, 2026, 9:54 PM EDT
Completed Phase 3 Interventional

A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension

NCT00465803
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
Travoprost 0.004%/timolol 0.5% ophthalmic solution, Travoprost ophthalmic solution, 0.004%, Timolol maleate ophthalmic solution, 0.5%
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Sep 2, 2026, 9:54 PM EDT
Completed No phase listed Observational

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

NCT04467931
View directory record Official record
Conditions
Hypertension, COVID
Interventions
ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
22,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Sep 2, 2026, 9:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effectiveness and Safety of Timolol and Dorzolamide Loaded Contact Lenses

NCT02852057
View directory record Official record
Conditions
Glaucoma
Interventions
timolol maleate and dorzolamide hydrochloride
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Sep 2, 2026, 9:54 PM EDT
Completed Phase 3 Interventional

A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma

NCT00277498
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
Xalacom, Xalatan, Timolol
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
64
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Artesia, California + 52 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 2, 2026, 9:54 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

NCT01177098
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
bimatoprost /timolol formulation A fixed combination ophthalmic solution, bimatoprost/timolol fixed combination ophthalmic solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Sep 2, 2026, 9:54 PM EDT
Completed Phase 2 Interventional

A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

NCT01917383
View directory record Official record
Conditions
Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions
Trabodenoson, Latanoprost, Timolol
Drug
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Bristol, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced Sep 2, 2026, 9:54 PM EDT
Terminated Phase 4 Interventional Results available

Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®

NCT02730871
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide/brimonidine vehicle, Travoprost 0.004%/timolol 0.5% solution
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Sep 2, 2026, 9:54 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Beta Blocker for Chronic Wound Healing

NCT00368602
View directory record Official record
Conditions
Ulcer, Burns
Interventions
Timoptic, Placebo
Drug · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Mather, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 2, 2026, 9:54 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

NCT00332540
View directory record Official record
Conditions
Ocular Hypertension
Interventions
bimatoprost/timolol fixed combination
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2011 · Synced Sep 2, 2026, 9:54 PM EDT
Completed Phase 4 Interventional Results available

Effect of Myocilin Genetic Variants on Intraocular Pressure and Pressure Variation in Sitting and Supine Positions

NCT00906087
View directory record Official record
Conditions
Glaucoma
Interventions
Cosopt (combination eyedrop of dorzolamide and timolol)
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 99 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Sep 2, 2026, 9:54 PM EDT
Completed Phase 4 Interventional Results available

Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®

NCT01170884
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution, bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 2, 2026, 9:54 PM EDT